Nordicus Partners CORP (NORD) — SEC Filings

Overview

Nordicus Partners CORP (NORD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 5, 2025: Nordicus Partners Corp. entered into a material definitive agreement on December 5, 2025. The company, formerly known as EKIMAS Corp, AdvanSource Biomaterials Corp, and CARDIOTECH INTERNATIONAL INC, is incorporated in Delaware and operates in management consulting services. The filing also notes unr

Sentiment Summary

Across 28 filings, the sentiment breakdown is: 1 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Nordicus Partners CORP is neutral.

Filing Type Overview

Nordicus Partners CORP (NORD) has filed 14 8-K, 6 10-Q, 2 10-K, 1 S-1/A, 1 S-1, 3 SC 13D/A, 1 SC 13D with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (28)

• Nordicus Partners Corp. Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 5, 2025 Risk: medium
  Nordicus Partners Corp. entered into a material definitive agreement on December 5, 2025. The company, formerly known as EKIMAS Corp, AdvanSource Biomaterials C
• Nordicus' Net Loss Widens to $2.7M Amid R&D Push, Board Expansion — 10-Q · Nov 14, 2025 Risk: high
  Nordicus Partners Corp (NORD) reported a significant increase in net loss for the six months ended September 30, 2025, reaching $2,718,360, a substantial rise f
• Nordicus Partners Corp. Files 8-K: Material Agreement & Equity Update — 8-K · Sep 19, 2025 Risk: medium
  Nordicus Partners Corp. entered into a Material Definitive Agreement on September 18, 2025. The company also reported on Unregistered Sales of Equity Securities
• Nordicus Partners Corp. 10-Q Filing for June 30, 2025 — 10-Q · Aug 20, 2025 Risk: medium
  Nordicus Partners Corp. filed its 10-Q for the period ending June 30, 2025. The filing includes financial data for the quarter and year-to-date, with specific d
• Nordicus Partners Corp. Files 8-K with Historical Name Changes — 8-K · Aug 11, 2025 Risk: low
  Nordicus Partners Corp. filed an 8-K on August 11, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing indicates the
• Nordicus Partners Corp. Announces Board and Executive Changes — 8-K · Aug 7, 2025 Risk: medium
  Nordicus Partners Corp. announced on August 7, 2025, changes in its board and executive team, including the departure of certain officers and the election of ne
• Nordicus Partners Navigates Capital Shifts in Latest 10-K — 10-K · Jul 29, 2025 Risk: medium
  Nordicus Partners Corp (NORD) filed its 10-K for the fiscal year ended March 31, 2025, revealing a continued focus on its management consulting services. While
• Nordicus Partners Corp Files 8-K — 8-K · Jul 3, 2025 Risk: low
  Nordicus Partners Corp. filed an 8-K on July 3, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial state
• Nordicus Partners Corp. Names New Director and CFO — 8-K · Jul 1, 2025 Risk: medium
  Nordicus Partners Corp. announced on July 1, 2025, the departure of director Robert J. Gaglini and the election of new director David M. Miller. The company als
• Nordicus Partners Corp Files 8-K — 8-K · Jun 11, 2025 Risk: low
  Nordicus Partners Corp. filed an 8-K on June 11, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial stat
• Nordicus Partners Corp. Files Q3 2024 10-Q — 10-Q · Apr 2, 2025 Risk: low
  Nordicus Partners Corp. filed a 10-Q for the period ending December 31, 2024. The company, formerly known as EKIMAS Corp, AdvanSource Biomaterials Corp, and CAR
• Nordicus Partners Corp Files 8-K — 8-K · Apr 1, 2025 Risk: low
  Nordicus Partners Corp. filed an 8-K on April 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known a
• Nordicus Partners Corp Files 8-K — 8-K · Mar 6, 2025 Risk: low
  Nordicus Partners Corp. filed an 8-K on March 6, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company,
• Nordicus Partners Corp Files 8-K — 8-K · Jan 2, 2025 Risk: low
  Nordicus Partners Corp. filed an 8-K on January 2, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Nordicus Partners Corp. Files S-1/A Amendment — S-1/A · Dec 23, 2024 Risk: medium
  Nordicus Partners Corp. filed an S-1/A amendment on December 23, 2024, detailing its business operations and financial status. The company, formerly known as EK
• Nordicus Partners Corp. Files S-1 for Public Offering — S-1 · Dec 10, 2024 Risk: medium
  Nordicus Partners Corp. filed an S-1 form on December 10, 2024, indicating a potential public offering. The company, formerly known as EKIMAS Corp, AdvanSource
• Nordicus Partners Corp. Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 3, 2024 Risk: medium
  Nordicus Partners Corp. entered into a Material Definitive Agreement on November 27, 2024. The company also reported on unregistered sales of equity securities
• Nordicus Partners Corp. Files Q2 2025 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Nordicus Partners Corp. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the compan
• Nordicus Partners Corp Completes Acquisition — 8-K · Nov 13, 2024 Risk: medium
  Nordicus Partners Corp. announced on November 13, 2024, the completion of an acquisition. The filing also details entry into a material definitive agreement and
• Alteral Therapeutics Amends Nordicus Partners Stake — SC 13D/A · Nov 5, 2024 Risk: medium
  Alteral Therapeutics ApS filed an amendment to its Schedule 13D on November 5, 2024, regarding its holdings in Nordicus Partners Corp. The filing indicates a ch
• GK Partners ApS Amends Nordicus Partners Stake — SC 13D/A · Aug 23, 2024 Risk: medium
  GK Partners ApS filed an amendment (No. 4) to its Schedule 13D on August 23, 2024, regarding its holdings in Nordicus Partners Corporation. The filing indicates
• Nordicus Partners Corp. Files Q1 2025 10-Q — 10-Q · Aug 19, 2024 Risk: low
  Nordicus Partners Corp. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the company, wh
• Nordicus Partners Corp Files 2024 10-K — 10-K · Jul 3, 2024 Risk: low
  Nordicus Partners Corp. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its financial performance and business operations. The company, f
• Alteral Therapeutics Files SC 13D for Nordicus Partners — SC 13D · Jun 5, 2024 Risk: medium
  Alteral Therapeutics ApS, located in Gentofte, Denmark, has filed a Schedule 13D on June 5, 2024, regarding their holdings in Nordicus Partners Corp. The filing
• Nordicus Partners Corp. Elects New Directors, Updates Executive Compensation — 8-K · Jun 4, 2024 Risk: low
  Nordicus Partners Corp. announced on June 4, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new direc
• Nordicus Partners Completes Asset Acquisition — 8-K · May 16, 2024 Risk: medium
  Nordicus Partners Corp. announced on May 16, 2024, the completion of its acquisition of certain assets from AdvanSource Biomaterials Corp. The filing also detai
• Rouf Amends Nordicus Partners Stake — SC 13D/A · Mar 26, 2024 Risk: medium
  Henrik Rouf, through Nordicus Partners Corp, has filed an amendment (Amendment No. 4) to Schedule 13D concerning Nordicus Partners Corporation (formerly known a
• Nordicus Partners Corp Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 6, 2024 Risk: low
  Nordicus Partners Corp (NORD) filed a Quarterly Report (10-Q) with the SEC on February 6, 2024. Nordicus Partners Corp filed a 10-Q report for the period ending

Risk Profile

Risk Assessment: Of NORD's 28 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Nordicus Partners CORP's most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: -$2,718,360
• EPS: N/A
• Debt-to-Equity: 0.17
• Cash Position: $242,155
• Operating Margin: N/A
• Total Assets: $75,882,821
• Total Debt: $11,215,508

Key Executives

• Allan Wehnert
• Torben S. Jensen
• Kim T. Mcke
• Andrew J. Ritter
• Robert J. Gaglini
• David M. Miller
• Michael J. McShane
• David M. Dykeman
• Robert J. Dykeman
• Sarah E. Dykeman
• Henrik Rouf

Industry Context

Nordicus Partners Corp operates as a business accelerator focused on Nordic life sciences companies. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this sector often rely on substantial external funding to advance preclinical and clinical development, with a high rate of failure but potential for significant returns upon successful commercialization.

Top Tags

material-agreement (7) · equity-sale (7) · financials (6) · 10-Q (5) · corporate-filing (4) · corporate-history (3) · 8-K (3) · sec-filing (3) · schedule-13d (3) · ownership-change (3)

Key Numbers

• Net Loss: $2,718,360 — Increased from $758,954 in prior year period
• Revenue: $0 — No revenue generated for the six months ended September 30, 2025
• Total Operating Expenses: $2,043,364 — Increased from $768,064 in prior year period
• Change in fair value of investment: $675,000 — New expense contributing to net loss
• Cash at September 30, 2025: $242,155 — Increased from $19,914 at March 31, 2025
• Proceeds from issuance of common stock: $2,419,220 — Primary source of cash inflow
• In-process research and development: $46,402,880 — Increased by $3,694,801 from March 31, 2025
• Common Stock Outstanding: 18,566,360 — As of November 12, 2025
• Total Assets: $75,882,821 — Increased from $70,246,329 at March 31, 2025
• Investment in Mag Mile Capital, Inc.: $1,250,000 — Decreased from $1,925,000 at March 31, 2025
• Fiscal Year End: 0331 — Indicates the end of the company's annual financial reporting cycle.
• Reporting Period End Date: 20250630 — The date through which financial information is reported in this 10-Q.
• Filing Date: 20250820 — The date this 10-Q was officially submitted to the SEC.
• Fiscal Year End Date: 2025-03-31 — The period covered by this 10-K filing.
• Central Index Key (CIK): 0001011060 — Unique identifier for Nordicus Partners Corp with the SEC.

Frequently Asked Questions